NEW YORK (GenomeWeb News) – Crown Bioscience and Horizon Discovery today announced that they will partner on offering new in vivo X-MAN models as a service to Crown's customers.

Horizon's X-MAN cell lines are used for in vivo and in vitro drug discovery model validation. The Cambridge, UK-baed firm already offers more than 450 X-MAN cell lines, as well as more than 50 phenotypic cell-based assays, and its SyntheTx drug/RNAi screening platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.